Miromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ Transplant

Miromatrix
Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email
Press Contacts

Investor Contact
Greg Chodaczek
347-620-7010
[email protected]

Media Contact:
[email protected]

EDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, applauds the U.S. Food and Drug Administration (FDA) for hosting a two-day public advisory committee meeting to discuss scientific and regulatory topics relating to the field of organ transplant, specifically xenotransplantation. Opening remarks from the FDA highlighted the limited availability of human organs for transplant and recognized the tremendous unmet need for new treatments for patients with end-stage organ failure.     

“We are appreciative of the FDA’s significant commitment of time and resources to discuss topics that may ultimately help address the extensive shortage of organs available for transplant. We are also excited by the possibility that our proprietary decellularization and recellularization technology may provide an additional treatment alternative for organ transplant patients,” said Jeff Ross Ph.D., Miromatrix’s CEO. “Our proprietary decellularization and recellularization technology platform was designed in such a manner that we believe it is not classified as xenotransplantation, and it may address some of the challenges that have historically faced xenotransplantation technologies, including gene editing technologies.”

Scott Nyberg M.D., Ph.D., a Mayo Clinic transplant surgeon and Miromatrix collaborator, added that “Miromatrix’s two-step method of decellularization and recellularization is designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells to reduce the risk of organ rejection amongst other potential benefits.”

The FDA published its original guidance for the xenotransplantation industry in 2003 and updated that guidance in 2016. The FDA noted that the updated guidance addresses many of the topics discussed during the two-day meeting and that the science is changing rapidly.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email
MEDICA 2022 banner

Where healthcare is going.
MEDICA 2022 – Top in all medical areas

We are at Hall 17 / A07

tradewinds booth location at MEDICA 2022

TradeWinds Consulting

Are you in?

Subscribe to receive exclusive content and notifications to your inbox